Albireo is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases in addition to other liver and gastrointestinal (GI) diseases. Its clinical pipeline includes two Phase II candidates and one Phase III candidate. Its lead product candidate, A4250, is currently being studied in a Phase II clinical trial in children with cholestatic liver disease that is designed to support Albireo’s planned future pivotal development in progressive familial intrahepatic cholestatasis (PFIC